[Aortic insufficiency under weak doses of cabergoline for non-tumoral hyperprolactinemia].
Used in its neurological indication, cabergoline is known to induce cardiac valve regurgitations, essentially mitral and aortic valvular diseases, by its action on the 5HT2b receptors. Until now, it was assumed that the dose and the duration of exposure were the major factors of appearance. We describe a case of aortic insufficiency which developed in a patient given low doses of cabergoline (0.5 mg weekly) for non-tumoral hyperprolactinemia. Because of previous use of appetite suppressants and of bromocriptine, the exclusive responsibility of cabergoline remained uncertain. The potential gravity of these valvular heart diseases emphasizes the importance of careful cardiologic examination before and during treatment.
Belleville
I
I
Service d'endocrinologie et maladies métaboliques, CHU de Dijon, hôpital du Bocage, boulevard Mal-de-Lattre-de-Tassigny, BP 77908, 21034 Dijon cedex, France. belleville.pro@wanadoo.fr
Chague
F
F
Petit
J-M
JM
Boujon
B
B
D001022:Aortic Valve Insufficiency / Q000188:drug therapy*; D000077465:Cabergoline; D003937:Diagnosis, Differential; D015259:Dopamine Agents / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006349:Heart Valve Diseases / Q000175:diagnosis; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D008875:Middle Aged; D044403:Receptor, Serotonin, 5-HT2B / Q000187:drug effects / Q000502:physiology
D015259:Dopamine Agents; D004873:Ergolines; D044403:Receptor, Serotonin, 5-HT2B; D000077465:Cabergoline